Maat Pharma (XPAR:MAAT) Debt-to-Asset : 0.34 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Maat Pharma Debt-to-Asset?

Maat Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €7.11 Mil. Maat Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €10.06 Mil. Maat Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was €50.92 Mil. Maat Pharma's debt to asset for the quarter that ended in Jun. 2024 was 0.34.

Maat Pharma Debt-to-Asset Historical Data

The historical data trend for Maat Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maat Pharma Debt-to-Asset Chart

Maat Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

1.28

0.25

0.12

0.25

0.33

Maat Pharma Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial						0.18	0.25	0.26	0.33	0.34

Competitive Comparison of Maat Pharma's Debt-to-Asset

For the Biotechnology subindustry, Maat Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maat Pharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maat Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Maat Pharma's Debt-to-Asset falls into.

Maat Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Maat Pharma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.455	+	10.62)	/	42.931
	=	0.33

Maat Pharma's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.107	+	10.064)	/	50.923
	=	0.34

Maat Pharma (XPAR:MAAT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Maat Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Maat Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Maat Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maat Pharma SA (XPAR:MAAT) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

4RD:Germany

Address

70 Avenue Tony Garnier, Lyon, FRA, 69007

Website

https://www.maatpharma.com

Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.

Maat Pharma Headlines

No Headlines